focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Lower open ahead of BoE, ECB; Currys swings to loss

Thu, 15th Dec 2022 07:49

(Alliance News) - Stock prices in London are set to open lower on Thursday, after the US Federal Reserve raised interest rates as expected and ahead of three more central bank decisions.

The Fed hiked rates by 50 basis points, as widely expected, but also forecast that interest rates will peak at a higher level than previously expected.

The Federal Open Market Committee lifted the target range for the federal funds rate to 4.25% to 4.50% - the highest since 2007 - from the previous range of 3.75% to 4.00%.

"The committee anticipates that ongoing increases in the target range will be appropriate in order to attain a stance of monetary policy that is sufficiently restrictive to return inflation to 2% over time," the Fed explained.

The Swiss National Bank will kick off Thursday's busy day for central bank decisions at 0830 GMT, before the Bank of England announces its interest rate decision at midday, followed shortly afterward by the European Central Bank.

China's retail sales plunged last month, official data showed, as Covid restrictions and a property market crisis hammered the world's second-largest economy.

The figures highlight the work ahead for the government as it moves away from almost three years of strict containment measures that have whittled growth and sent shudders through supply chains.

November retail sales sank 5.9% year-on-year, marking the second successive contraction, according to data released by the National Bureau of Statistics.

In early company news in London, electronics retailer Currys fell into a half-year loss, due to an impairment. Outsourcer Serco raised its 2022 guidance, and oil field services provider Hunting raised 2023 guidance.

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called down 27.63 points, or 0.4%, at 7,468.30

----------

Hang Seng: down 1.5% at 19,373.22

Nikkei 225: closed down 0.4% at 28,051.70

S&P/ASX 200: closed down 0.6% at 7,204.80

----------

DJIA: closed down 0.4%, at 33,966.35

S&P 500: closed down 0.6% at 3,995.32

Nasdaq Composite: closed down 0.8% at 11,170.89

----------

EUR: lower at USD1.0652 (USD1.0660)

GBP: lower at USD1.2387 (USD1.2410)

USD: higher at JPY135.77 (JPY134.82)

Gold: lower at USD1,792.36 per ounce (USD1,810.74)

(Brent): lower at USD82.00 a barrel (USD82.51)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

14:15 CET EU ECB interest rate announcement

11:00 GMT Ireland goods exports and imports

12:00 GMT UK BoE MPC meeting minutes

12:00 GMT UK interest rate decision

08:30 EST US advance monthly sales for retail and food services

08:30 EST US Philadelphia Fed business outlook survey

08:30 EST US unemployment insurance claims report

08:30 EST US weekly export sales

09:15 EST US industrial production

16:00 EST US treasury international capital data

16:30 EST US Foreign Central Bank holdings

16:30 EST US federal discount window borrowings

----------

Tens of thousands of nurses are going on strike for the first time across England, Wales and Northern Ireland. Picket lines are being set up at dozens of hospitals in a dispute over pay, with the Welsh government saying services will be "significantly impacted". Thousands of NHS appointments and operations have been cancelled because of the strike, with the health service running a bank holiday-style service in many areas. The Royal College of Nursing has said it will still staff chemotherapy, emergency cancer services, dialysis, critical care units, neonatal and paediatric intensive care. Some areas of mental health and learning disability and autism services are also exempt, while trusts have been told they can request staffing for specific clinical needs. When it comes to adult A&E and urgent care, nurses will work Christmas Day-style rotas.

----------

BROKER RATING CHANGES

----------

Deutsche Bank raises AstraZeneca price target to 13,000 (12,000) pence - 'buy'

----------

Goldman Sachs raises Big Yellow to 'buy' ('neutral') - price target 1,250 (1,130) pence

----------

Barclays raises Victorian Plumbing to 'overweight' ('equal-weight') - price target 100 (75) pence

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm AstraZeneca, alongside US peer Merck & Co, announced that the US Food & Drug Administration will extend the Prescription Drug User Fee Act date by three months to allow further time for a full review of the supplementary new drug application of Lynparza in combination with abiraterone and prednisone or prednisolone. The review is for Lynparza in combination for the treatment of metastatic castration-resistant prostate cancer.

----------

SSE's SSEN Transmission arm welcomed UK Ofgem's approval of transmission investments needed to meet the UK government's 50 gigawatt offshore wind target by 2030. The electricity provider said the decision by the regulator confirms that all SSEN transmission projects will be taken forward as part of the Accelerated Strategic Transmission Investment framework. As a result, two 2 gigawatt subsea high-voltage direct current links will be taken forward as joint ventures with National Grid Electricity Transmission, amongst other projects. Ofgem also confirmed these will be exempt from proposals to introduce competitive ownership of onshore electricity networks. National Grid said it welcomed the clarity that the Ofgem decision gives to NGET. Ofgem said the ASTI framework streamlines the onshore transmission regulatory approval process in the UK.

----------

COMPANIES - FTSE 250

----------

Currys swung sharply to a loss in the six months ended October 29, as revenue declined. The electricals retailer posted a pretax loss of GBP548 million, swinging from a profit of GBP48 million in the previous year. Revenue fell to GBP4.47 billion from GBP4.79 million. More significantly, Currys booked an impairment of goodwill of GBP511 million in the half-year, compared to no such impairment a year before. It said this arose at the time of the Dixons Carphone merger in 2014. Currys also noted lower international profits and margin for the swing to a loss. The company now expects full-year pretax profit to be between GBP100 million and GBP125 million. In the first six weeks of the second half, trading has been in-line with the first half.

----------

Outsourcer Serco said it expects its 2022 results to be "slightly" ahead of previous guidance and added its 2023 results are due to be in-line with expectations. Revenue for 2022 is expected at GBP4.5 billion, Serco said, slightly above 2021 despite a reduction in Covid-related revenue. Underlying trading profit is expected at GBP235 million, representing a GBP5 million increase on the firm's previous guidance. For 2023, underlying trading profit is expected to be similar to 2022 at GBP235 million. Chief Executive Rupert Soames said: "2022 will turn out much better than we expected at the start of the year as strong growth across the business largely replaced Covid contracts. Revenue is expected to be 8% higher and underlying trading profit around 20% better than we anticipated when we first gave guidance in December 2021." Soames steps down at the end of the year, replaced by Mark Irwin, currently CEO of Serco's UK & Europe business.

----------

OTHER COMPANIES

----------

Hunting said that its 2022 trading and financial outturn remains in-line with market expectations, with earnings before interest, tax, depreciation and amortisation predicted at USD50 million. The oil and gas industry services provider added that its sales order book continues to improve, with the order book now approaching USD500 million. For 2023, Hunting raised guidance for Ebitda to between USD85 million and USD90 million, up from USD80 million previously. Chief Executive Jim Johnson said: "2022 has been a year of rebuilding for the industry with 2023 now likely to be a strong year of growth for the group. All of our operating segments are reporting good levels of enquiries, and with our order book now approaching USD500 million, our earnings visibility for the year ahead is robust, despite recessionary fears."

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.